Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Prospective, Multi-Center, Randomized, Two-Arm, Active Controlled, Double-Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of Serum Institute of India 10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Indian PCV-Naive Toddlers (12 to 15 months)

X
Trial Profile

A Phase 2, Prospective, Multi-Center, Randomized, Two-Arm, Active Controlled, Double-Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of Serum Institute of India 10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Indian PCV-Naive Toddlers (12 to 15 months)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SIILPCV10 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Bacteraemia; Meningitis; Otitis; Pneumococcal infections; Pneumonia; Sepsis; Streptococcal infections
  • Focus Adverse reactions
  • Sponsors Serum Institute of India
  • Most Recent Events

    • 26 Mar 2019 Status changed from not yet recruiting to completed.
    • 26 Aug 2016 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top